Redeye leaves a short comment on InDex Pharmaceuticals following yesterday evening's announcement that patient recruitment for the phase III study is planned to initiate after the summer. This is a minor delay, but it has a limited impact. We reiterate our Base case of SEK 4.5 following the announcement.